Genetic susceptibility to fixed drug eruption: evidence for a link with HLA-B22.

Abstract

BACKGROUND:

Our observation of familial cases of fixed drug eruption (FDE) prompted us to consider a genetic predisposition to this disease.

OBJECTIVE:

Our purpose was to determine whether there is any association between FDE and any of the major histocompatibility complex class I or II alleles.

METHODS:

HLA class I and II typing was performed by lymphocytotoxicity assay in 36 unrelated patients with FDE.

RESULTS:

Significantly higher (p < 0.0001) frequencies of the B22 and Cw1 antigens were found in the 36 patients with FDE.

CONCLUSION:

Our data are the first to suggest a genetic predisposition to FDE.

• Authors: R Pellicano, G Ciavarella, M Lomuto, G Di Giorgio
• Journal: Journal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 30 Issue 1 Pg. 52-4 (Jan 1994) ISSN: 0190-9622 [Print] United States
• PMID: 8277031 (Publication Type: Journal Article)

Chemical References

• HLA-B Antigens
• Feprazone

Topics

• Adolescent
• Adult
• Aged
• Child
• Disease Susceptibility
• Drug Eruptions (genetics)
• Family
• Female
• Feprazone (adverse effects)
• HLA-B Antigens (genetics)
• Humans
• Male
• Middle Aged
• Phenotype
• Skin Tests